{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:03:55Z","timestamp":1790539435103,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.tem.2016.04.014","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T20:29:31Z","timestamp":1464121771000},"page":"470-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Current and Emerging Aspects of Diabetes Mellitus in Acromegaly"],"prefix":"10.1016","volume":"27","author":[{"given":"Stefano","family":"Frara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Maffezzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2016.04.014_bib0620","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2016.04.014_bib0625","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","article-title":"A consensus on the diagnosis and treatment of acromegaly complications","volume":"16","author":"Melmed","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib0630","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2016.04.014_bib0635","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00592-014-0635-6","article-title":"Insulin and GH\u2013IGF-I axis: endocrine pacer or endocrine disruptor?","volume":"52","author":"Giustina","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.tem.2016.04.014_bib0640","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11102-010-0281-0","article-title":"Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population","volume":"14","author":"Rosario","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib0645","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0650","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptin-e: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2016.04.014_bib0655","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0660","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0670","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2265.2001.01206.x","article-title":"Relationship between blood pressure and glucose tolerance in acromegaly","volume":"54","author":"Jaffrain-Rea","year":"2001","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0675","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2016.04.014_bib0680","first-page":"1301","article-title":"Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy","volume":"74","author":"Giustina","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0685","first-page":"1369","article-title":"Effects of sex and age on the growth hormone response to galanin in healthy human subjects","volume":"76","author":"Giustina","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0690","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1530\/eje.0.1330646","article-title":"Influence of thyroid hormones on the regulation of growth hormone secretion","volume":"133","author":"Giustina","year":"1995","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0695","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000127172","article-title":"Effects of food deprivation on the GH axis: immunocytochemical and molecular analysis","volume":"65","author":"Brogan","year":"1997","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2016.04.014_bib0700","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0705","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/diabetes.50.10.2301","article-title":"Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure","volume":"50","author":"Nielsen","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.tem.2016.04.014_bib0710","first-page":"936","article-title":"Growth hormone inhibits lipoprotein lipase activity in human adipose tissue","volume":"80","author":"Ottosson","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0715","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0026-0495(94)90273-9","article-title":"Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II diabetic patients","volume":"43","author":"Giustina","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.tem.2016.04.014_bib0720","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2007-2780","article-title":"Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly","volume":"93","author":"Freda","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0725","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1152\/ajpendo.1986.250.3.E269","article-title":"Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action","volume":"250","author":"Hansen","year":"1986","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0730","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1210\/jc.2008-2086","article-title":"Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly","volume":"94","author":"Higham","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0735","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/db06-0299","article-title":"Growth hormone regulation of p85\u03b1 expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance","volume":"56","author":"del Rincon","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.tem.2016.04.014_bib0740","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tem.2016.02.005","article-title":"The impact of adipose tissue on insulin resistance in acromegaly","volume":"27","author":"Olarescu","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0745","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Impaired-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients","volume":"52","author":"Kasayama","year":"2000","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0750","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","article-title":"Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients","volume":"17","author":"Alexopoulou","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib0755","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/EJE-10-1096","article-title":"Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery in pancreatic \u03b2-cell function is preserved","volume":"164","author":"Kinoshita","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0760","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry","volume":"164","author":"Fieffe","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0765","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11102-010-0284-x","article-title":"Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism","volume":"14","author":"Espinosa-de-los-Monteros","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib0770","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0775","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EC-14-0021","article-title":"Prevalence of diabetes mellitus in patients with acromegaly","volume":"3","author":"Dreval","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.tem.2016.04.014_bib0780","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes \u2013 2014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2016.04.014_bib0785","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00592-009-0112-9","article-title":"Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities","volume":"46","author":"Resmini","year":"2009","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.tem.2016.04.014_bib0790","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0795","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12020-014-0436-2","article-title":"Prediabetes and associated disorders","volume":"48","author":"Buysschaert","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0800","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1210\/jc.2012-2896","article-title":"The metabolic profile in active acromegaly is gender-specific","volume":"98","author":"Ciresi","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0805","first-page":"526","article-title":"Criteria for cure of acromegaly: a consensus statement","volume":"85","author":"Giustina","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0810","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0815","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2004-2009","article-title":"Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly","volume":"90","author":"Puder","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0820","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11102-012-0396-6","article-title":"Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly","volume":"16","author":"Niculescu","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib0825","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1507\/endocrj.EJ14-0254","article-title":"The prevalence of acromegaly in hospitalized patients with type 2 diabetes","volume":"62","author":"Suda","year":"2015","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2016.04.014_bib0830","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege","volume":"91","author":"Daly","year":"2006","journal-title":"Belgium. J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0835","doi-asserted-by":"crossref","first-page":"e115184","DOI":"10.1371\/journal.pone.0115184","article-title":"Whole-body insulin sensitivity rather than body-mass-index determines fasting and post-glucose-load growth hormone concentrations","volume":"17","author":"Anderwald","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tem.2016.04.014_bib0840","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0845","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/BF03349263","article-title":"Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults","volume":"31","author":"Giustina","year":"2008","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.tem.2016.04.014_bib0850","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"A consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0855","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0860","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","article-title":"Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed","volume":"72","author":"Reid","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0865","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12020-014-0282-2","article-title":"Safety and specificity of the growth hormone suppression test in patients with diabetes","volume":"48","author":"Rosario","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0870","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/1043-2760(94)90005-1","article-title":"Growth hormone neuroregulation in diabetes mellitus","volume":"5","author":"Giustina","year":"1994","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0875","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1507\/endocrj.K06-083","article-title":"Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia","volume":"54","author":"Lim","year":"2007","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2016.04.014_bib0880","first-page":"1296","article-title":"Galanin decreases circulating growth hormone levels in acromegaly","volume":"74","author":"Giustina","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0885","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000144046","article-title":"Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: efficacy and safety of the galanin test","volume":"88","author":"Mazziotti","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2016.04.014_bib0890","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.mpmed.2014.09.007","article-title":"Epidemiology of diabetes","volume":"42","author":"Forouhi","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.tem.2016.04.014_bib0895","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications","volume":"35","author":"Kamenick\u00fd","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2016.04.014_bib0900","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0026-0495(00)80040-2","article-title":"Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog","volume":"49","author":"Manelli","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.tem.2016.04.014_bib0905","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archopht.1956.00930040424009","article-title":"Hypophysectomy for diabetic retinopathy; a preliminary report","volume":"56","author":"Schimek","year":"1956","journal-title":"AMA Arch. Ophthalmol."},{"key":"10.1016\/j.tem.2016.04.014_bib0910","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1210\/jc.2007-1213","article-title":"Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0915","first-page":"206","article-title":"Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction","volume":"47","author":"Ragonese","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0920","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12020-015-0628-4","article-title":"Low risk of coronary artery disease in patients with acromegaly","volume":"50","author":"Dos Santos Silva","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-013-0157-y","article-title":"Insight into cardiovascular risk factors in patients with acromegaly","volume":"47","author":"Fleseriu","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0930","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1463-1326.2007.00709.x","article-title":"The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease","volume":"10","author":"Ezzat","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0935","first-page":"193","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy","volume":"85","author":"Colao","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0940","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-012-9828-3","article-title":"QT dispersion in patients with acromegaly","volume":"43","author":"Unubol","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0945","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12020-012-9623-1","article-title":"A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy","volume":"41","author":"Zhang","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0950","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","article-title":"Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease","volume":"159","author":"Davi\u2019","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib0955","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2009-1912","article-title":"Endocrine aspects of obstructive sleep apnea","volume":"95","author":"Attal","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0960","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12020-016-0890-0","article-title":"Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0965","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1210\/jc.2014-2937","article-title":"Bone turnover, bone mineral density and fracture risk in acromegaly: a meta-analysis","volume":"100","author":"Mazziotti","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0970","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1210\/jc.2013-1460","article-title":"Vertebral fractures in patients with acromegaly: a 3-year prospective study","volume":"98","author":"Mazziotti","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0975","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1210\/jc.2008-0791","article-title":"Prevalence of vertebral fractures in men with acromegaly","volume":"93","author":"Mazziotti","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0980","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1210\/er.2012-1042","article-title":"The impact of diabetes and diabetes medications on bone health","volume":"36","author":"Gilbert","year":"2015","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2016.04.014_bib0985","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1210\/jc.2012-4073","article-title":"Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography","volume":"98","author":"Madeira","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib0990","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","article-title":"Influence of diabetes mellitus in vertebral fractures in men with acromegaly","volume":"40","author":"Mazziotti","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib0995","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000341761","article-title":"Growth hormone and cell growth","volume":"23","author":"Waters","year":"2012","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.tem.2016.04.014_bib1000","doi-asserted-by":"crossref","first-page":"e0127276","DOI":"10.1371\/journal.pone.0127276","article-title":"The role of diabetes in acromegaly associated neoplasia","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tem.2016.04.014_bib1005","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes care and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2016.04.014_bib1010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12020-013-9973-3","article-title":"Metabolic syndrome and endometrial cancer: a meta-analysis","volume":"45","author":"Esposito","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s12020-013-9939-5","article-title":"Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis","volume":"44","author":"Esposito","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1210\/jcem-27-10-1418","article-title":"Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment","volume":"27","author":"S\u00f6nksen","year":"1967","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3346\/jkms.2012.27.2.177","article-title":"The ability of \u03b2-cell to compensate for insulin resistance is restored with a reduction in excess growth hormone in Korean acromegalic patients","volume":"27","author":"Kim","year":"2012","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.tem.2016.04.014_bib1030","first-page":"348","article-title":"Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas","volume":"79","author":"Arafah","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tem.2014.10.005","article-title":"Growth hormone deficiency in treated acromegaly","volume":"26","author":"Mazziotti","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jc.2013-2394","article-title":"Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH \u2013 an update","volume":"99","author":"Gazzaruso","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2265.2012.04361.x","article-title":"Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly","volume":"77","author":"Lin","year":"2012","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib1050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","article-title":"Current management practices for acromegaly: an international survey","volume":"14","author":"Giustina","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib1055","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","article-title":"Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors","volume":"23","author":"Giustina","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tem.2016.04.014_bib1060","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/BF03345491","article-title":"Effects of two different somatostatin analogs on glucose tolerance in acromegaly","volume":"25","author":"Ronchi","year":"2002","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.tem.2016.04.014_bib1070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib1075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib1080","doi-asserted-by":"crossref","first-page":"E1010","DOI":"10.1152\/ajpendo.2000.278.6.E1010","article-title":"Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum","volume":"278","author":"Hansen","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1085","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tem.2016.04.014_bib1090","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1095","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide C2402 Study Group","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib1100","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","author":"Schmid","year":"2016","journal-title":"Endocrine."},{"key":"10.1016\/j.tem.2016.04.014_bib1105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib1110","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1517\/14656566.2013.847090","article-title":"Octreotide for acromegaly treatment: a reappraisal","volume":"14","author":"Giustina","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.tem.2016.04.014_bib1115","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","article-title":"Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline","volume":"37","author":"Giustina","year":"2014","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.tem.2016.04.014_bib1120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12020-014-0462-0","article-title":"Optimal use of pegvisomant in acromegaly: are we getting there?","volume":"8","author":"Giustina","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12020-014-0393-9","article-title":"ACROSTUDY: the Italian experience","volume":"48","author":"Grottoli","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0035-1569277","article-title":"Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients","volume":"48","author":"Jonas","year":"2016","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.tem.2016.04.014_bib1135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-13-0032","article-title":"Effects of medical therapies for acromegaly on glucose metabolism","volume":"169","author":"Urbani","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2016.04.014_bib1140","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-007-0037-7","article-title":"Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA","volume":"10","author":"De Marinis","year":"2007","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2016.04.014_bib1150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","article-title":"Cabergoline treatment in acromegaly: pros","volume":"46","author":"Marazuela","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1165","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF00186626","article-title":"Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion","volume":"71","author":"Rau","year":"1993","journal-title":"Clin. Investig."},{"key":"10.1016\/j.tem.2016.04.014_bib1170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-015-0404-6","article-title":"Italian Society for the Study of Diabetes (SID)\/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly","volume":"39","author":"Baroni","year":"2016","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.tem.2016.04.014_bib1175","article-title":"The role of patient education in the prevention and management of type 2 diabetes: an overview","author":"Coppola","year":"2015","journal-title":"Endocrine."},{"key":"10.1016\/j.tem.2016.04.014_bib1180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12020-013-9884-3","article-title":"Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?","volume":"44","author":"Majumdar","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1185","first-page":"154","article-title":"Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia","volume":"35","author":"Cambuli","year":"2012","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.tem.2016.04.014_bib1190","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.tem.2016.04.014_bib1195","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.tem.2016.04.014_bib1200","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2016.04.014_bib1205","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","article-title":"Drug-induced osteoporosis: mechanisms and clinical implications","volume":"123","author":"Mazziotti","year":"2010","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tem.2016.04.014_bib1210","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.2174\/1381612054546879","article-title":"Insulin secretagogues, sulfonylurea receptors and KATP channels","volume":"11","author":"Bryan","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tem.2016.04.014_bib1215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2016.04.014_bib1220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-014-0461-1","article-title":"Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?","volume":"48","author":"Mabilleau","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2016.04.014_bib1225","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","article-title":"Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use","volume":"49","author":"Kurtzhals","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.tem.2016.04.014_bib1230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/dmrr.912","article-title":"Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells","volume":"25","author":"Weinstein","year":"2008","journal-title":"Diabetes Metab. Res. Rev."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276016300418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276016300418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T16:02:12Z","timestamp":1567958532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276016300418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":123,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1043276016300418"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2016.04.014","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Emerging Aspects of Diabetes Mellitus in Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2016.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}